PA
PRME icon

Parallel Advisors’s Prime Medicine PRME Stock Holding History

Parallel Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110
Closed -$219 – 3672
2025
Q1 		$219 Buy
+110
New +$281 ﹤0.01% 3369

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Parallel Advisors's PRME Position: Q2 2025 in Review

Parallel Advisors sold out of Prime Medicine (PRME) in Q2 2025, closing a stake of 110 shares — an estimated $219 sold.

Parallel Advisors first reported a position in PRME in Q1 2025 and held it in 1 quarter. The position peaked at $219 in Q1 2025. 121 funds tracked by Wall St. Rank hold PRME as of Q2 2025.

  • Parallel Advisors reported no remaining Prime Medicine position as of Q2 2025 after selling out during the quarter.
  • Parallel Advisors sold 110 Prime Medicine shares in Q2 2025, an estimated $219.
  • Parallel Advisors first reported a position in Prime Medicine in Q1 2025 and held it in 1 quarter.
  • Parallel Advisors's Prime Medicine position peaked at $219 in Q1 2025.
  • 121 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2025.

Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.